𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development and validation of the Crohn's disease perceived work disability questionnaire

✍ Scribed by Mercedes Vergara; Antonia Montserrat; Francesc Casellas; Olga Gallardo; David Suarez; Jaume Motos; Albert Villoria; Mireia Miquel; Eva Martinez-Bauer; Xavier Calvet


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
189 KB
Volume
17
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis


Background: No validated instruments have been developed to measure work disability in Crohn's disease (CD). The aim of our study was to develop and validate a CD perceived work disability questionnaire (CPWDQ).

Methods: Development phase: an initial questionnaire containing 52 items was obtained from patients' interviews plus additional sources; it was completed by 106 patients and the 16 most significant items were selected using a psychometric method in order to create the CPWDQ. Validation phase: The validation assessed the questionnaire's convergent validity, discriminant validity, test-retest reproducibility, and internal consistency in 108 patients. Spearman rank correlation, t-test, intraclass correlation, and Cronbach's alpha were used for the analysis.

Results: Convergent validity was confirmed by good correlations between the CPWDQ and: clinical activity (r ΒΌ 0.59, P < 0.01), the Short Inflammatory Bowel Disease Questionnaire, IBDQ-9, (r ΒΌ 0.76, P < 0.001), Euroqol-5D (r ΒΌ 0.53, P < 0.01), and overall work impairment (WPAI_CD) r ΒΌ 0.66 (P < 0.01). Discriminant validity: CPWQ scores were higher in patients expected to have more severe disability, that is, in patients with active disease (n ΒΌ 38) 32.3 6 7.3 versus inactive (n ΒΌ 70) 22.6 6 5.9 (P < 0.001), in those requiring previous sick leave 30.7 6 7.5 (n ΒΌ 45) versus no sick leave 22.6 6 6.6 (n ΒΌ 63) (P < 0.01), and in those requiring hospitalization 32.2 6 8.6 (n ΒΌ 18) versus no hospitalization 24.7 6 7.1 (n ΒΌ 90) (P < 0.01). Internal consistency was also good (Cronbach's alpha ΒΌ 0.89). Reproducibility: CPWDQ measures obtained 2 weeks apart showed an excellent intraclass correlation coefficient: 0.89 (95% CI: 0.83-0.93).

Conclusions:

The CPWDQ seems to be a valid, reliable tool for measuring subjective work disability in CD.


πŸ“œ SIMILAR VOLUMES


Validation of the mainland Chinese versi
✍ W.H. Ren; M. Lai; Y. Chen; E.J. Irvine; Y.X. Zhou πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 103 KB

## Background: Inflammatory bowel disease affects the quality of a patient's life in many ways, but no validated instrument for measuring disease-specific quality of life in these patients is available for use in mainland china. the aim of our study was to develop and validate the mainland chinese

Development and validation of a question
✍ Aharon Tziner; Gary P. Latham; Bruce S. Price; Robert Haccoun πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 792 KB

A 25-item scoring instrument was developed to measure perceptions of the extent to which performance appraisals are affected by organizational politics. The survey was administered to 157 francophone managers. A factor analysis revealed that the perceptions of the extent to which political considera

Development and validation of the overac
✍ Elisabeth Piault; Christopher J. Evans; Derek Espindle; Zoe Kopp; Linda Brubaker πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 181 KB

## Abstract ## Aims To develop and validate a measure of patient satisfaction with treatment in overactive bladder: the Overactive Bladder Satisfaction Questionnaire (OAB‐S). ## Methods Development of the questionnaire included a comprehensive literature review, development of a conceptual model

Short CDAI: Development and validation o
✍ Kelvin Thia; William A. Faubion Jr; Edward V. Loftus Jr; Tore Persson; Anders Pe πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 1 views

## Background: The aim of this study was to develop a shortened Crohn's Disease Activity Index (CDAI). Methods: A short CDAI was developed retrospectively using patient-level data from four budesonide clinical trials to select variables from the full CDAI which best predicted health-related quali